 |
|
The Risk of Cardiovascular Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus
Charles T. Valmadrid, MD, MPH;
Ronald Klein, MD, MPH;
Scot E. Moss, MA;
Barbara E. K. Klein, MD, MPH
Arch Intern Med. 2000;160:1093-1100.
ABSTRACT
| |
Background Despite the numerous studies on the relation of albuminuria with increased risk of all-cause mortality in type 2 diabetes mellitus, it remains uncertain whether microalbuminuria and/or gross proteinuria are independent risk factors for cardiovascular mortality. Moreover, the association of albuminuria with cardiovascular mortality in people with type 2 diabetes mellitus has not been well described in US populations.
Objective To estimate the relative risks (RRs) for the associations of microalbuminuria and gross proteinuria with cardiovascular disease mortality among persons with older-onset diabetes mellitus.
Methods We conducted a prospective cohort study of 840 people with older-onset diabetes mellitus who provided urine samples in the 1984-1986 examination of a population-based study of diabetic persons. The presence of microalbuminuria was determined by an agglutination inhibition assay and gross proteinuria by a reagent strip. The main outcome was time to mortality from cardiovascular disease, as determined from death certificates.
Results Of the 840 older-onset diabetic persons, 54.8% had normoalbuminuria, while 24.8% had microalbuminuria and 20.5% had gross proteinuria. During the 12-year follow-up (6127 person-years), we identified 364 deaths from cardiovascular disease. Compared with persons with normoalbuminuria, those with microalbuminuria and gross proteinuria had significantly higher risks of cardiovascular mortality. The RR as controlled for age, sex, glycemic control, insulin use, alcohol intake, physical activity, cardiovascular disease history, antihypertensive use, and retinopathy severity, was 1.84 (95% confidence interval [CI], 1.42-2.40) for those with microalbuminuria and 2.61 (95% CI, 1.99-3.43) for those with gross proteinuria. Further adjustment for other factors did not change the relations we found. When the end point used was mortality from coronary heart disease, stroke, or all causes, the increased risks were significant for both microalbuminuria (adjusted RRs [95% CIs], 1.96 [1.42-2.72], 2.20 [1.29-3.75], and 1.68 [1.35-2.09], respectively) and gross proteinuria (adjusted RRs [95% CIs], 2.73 [1.95-3.81], 2.33 [1.28-4.24], and 2.47 [1.97-3.10], respectively).
Conclusions Results from our population-based study strongly suggest that both microalbuminuria and gross proteinuria were significantly associated with subsequent mortality from all causes and from cardiovascular, cerebrovascular, and coronary heart diseases. These associations were independent of known cardiovascular risk factors and diabetes-related variables.
INTRODUCTION
CARDIOVASCULAR DISEASE is the leading cause of death among individuals with type 2 diabetes mellitus.1 Many follow-up studies involving patients with type 2 diabetes mellitus have demonstrated the relation of both microalbuminuria2-19 and clinical proteinuria2, 4-5,13, 20-28 with increased risk of mortality, which is largely due to cardiovascular diseases. However, some of these studies had a small number of participants or short follow-up periods. Whether their effects on cardiovascular mortality were independent of known cardiovascular risk factors and other variables related to diabetes15-16,19, 29-30 or evident only in the earlier periods of follow-up as suggested by previous studies on total mortality8, 19 remains in question. Moreover, the excess risk of cardiovascular mortality associated with microalbuminuria or gross proteinuria in people with type 2 diabetes mellitus has not been well described, especially in US populations.
The large cohort of persons with older-onset diabetes mellitus in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) offers the opportunity to investigate the role of proteinuria in cardiovascular disease mortality in a US population. The aims of the present study are to estimate the relative risk (RR) of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria and to examine whether their effects are independent of known diabetes-related and cardiovascular risk factors in a population-based cohort of persons with older-onset diabetes mellitus.
SUBJECTS AND METHODS
STUDY SAMPLE AND PROCEDURES
The WESDR has been described in detail in earlier articles.31-36 Participants in this population-based study of diabetic persons were selected from an 11-county area in southern Wisconsin. Lists of all diabetic patients cared for from July 1, 1979, to June 30, 1980, were obtained from 452 of 457 primary care physicians practicing in the area. Eligibility criteria were determined from a systematic chart review, of which a representative sample of 2990 people was chosen for the baseline examination from 1980 to 1982. This included all 1210 patients with type 1 diabetes mellitus who were taking insulin (diagnosed before the age of 30 years) and a probability sample of 1780 persons with older-onset diabetes mellitus (diagnosed at 30 years of age or later). Follow-up interviews and/or examinations were done in 1984-1986, 1990-1992, and 1995-1996. The subject of these analyses was the older-onset group, of which 1370 participated in the baseline examination. Of these, 1.5% refused to participate in the 1984-1986 follow-up examination, and 0.4% were lost to follow-up, 1.2% had an interview only, and 24.8% of the original cohort had died.35 The analyses in this report were on the remaining 987 persons who returned for the follow-up examination done in 1984-1986, when information on microalbuminuria was first obtained.37
Pertinent parts of the 1984-1986 examination consisted of standardized methods for measuring height, weight, and blood pressure38; dilating the pupils and taking stereoscopic color fundus photographs of 7 standard fields for determining the presence and severity of diabetic retinopathy39; and taking blood samples for standardized measurements of glycosylated hemoglobin,40 serum creatinine, and plasma C peptide41 for the whole cohort and total serum cholesterol42 and high-density lipoprotein cholesterol (HDL-C)43 for a subset of the cohort.44 The glycosylated hemoglobin A1 microcolumn results of the WESDR were related to the Diabetes Control and Complications Trial (DCCT) glycosylated hemoglobin A1c values by the following equation: DCCT=0.003 + 0.935 x WESDR.45 Serum creatinine was measured by the modified Jaffe reaction using a centrifugal analyzer (Cobas FARA; Roche Diagnostic System, Division of Hoffmann LaRoche, Nutley, NJ) and standard reagents (Boehringer Mannheim Diagnostics, Indianapolis, Ind). The imprecision of the creatinine assay was determined as 2.73% (SD, ±0.03%) and 1.45% (SD, ±0.09%) on the basis of repeated (n=140) measurement controls, with values of 97 µmol/L (1.1 mg/dL) and 546 µmol/L (6.2 mg/dL), respectively. The method was determined to be linear to more than 1760 µmol/L (20.0 mg/dL). Single-voided, casual, fresh urine samples were collected for the determination of microalbuminuria and gross proteinuria.37, 46-47 Microalbuminuria was defined as having urinary albumin concentrations of at least 0.03 g/L using an agglutination inhibition assay (AlbuScreen; Cambridge Life Sciences, Cambridge, England),37, 46 and gross proteinuria was defined as having urinary protein concentrations of at least 0.3 g/L using a reagent strip (Labstix; Ames Division, Miles Inc, Elkhart, Ind).47 A structured interview was administered for questions on smoking, physical activity, and intake of alcohol, aspirin, digoxin, nitroglycerin, and medications for the control of blood glucose and blood pressure. Any questions regarding medication use were verified by a physician's report. All procedures were performed in a mobile van in or near the city in which the participants lived or, if not possible, in other settings, such as a clinic, hospital, nursing home, or home. The study was approved by the Human Subjects Committee of the University of Wisconsin, Madison.
ASCERTAINMENT OF DEATHS FROM CARDIOVASCULAR DISEASES
Mortality from cardiovascular disease was ascertained from ongoing mortality surveillance of the WESDR cohort, which consisted of reviews of daily newspaper obituaries and regular contact with study participants and their relatives, designated contact persons, or physicians. Deaths were confirmed with death certificate data from annual requests made to the Wisconsin Center for Health Statistics, Section of Vital Statistics. For this study, state mortality records through 1996 have been searched. The names of persons who had moved out of Wisconsin and those who had been lost to follow-up or were suspected to have died were submitted for matching against Wisconsin death records and the National Death Index. For each match made, a copy of the death certificate was secured from the appropriate state. Only deaths that had been confirmed by death certificates were included in the definition of cardiovascular mortality. Persons who were thought to be deceased but for whom a death certificate could not be obtained were considered to be alive as of the last contact date they were known to be alive.
Death certificates were collected and coded by trained nosologists using the International Classification of Diseases, Ninth Revision (ICD-9).48 Deaths were classified as due to cardiovascular disease when hypertensive heart disease, ischemic heart disease, heart failure, and/or cerebrovascular disease (ICD-9 codes 402, 404, 410-414, 428, 430-438) were mentioned as the underlying or contributory cause of death listed on the death certificates. Our preliminary analysis involving deaths due to cardiovascular disease as the "underlying cause" of death showed results similar to those based on "any mention" of cardiovascular disease as a cause of death on the death certificates, as was shown by others who conducted studies with general populations.49 Because of this and the advantage of having a higher number of events over those based solely on the underlying cause of death, this article presents the findings using any mention of cardiovascular disease as the end point.
DATA ANALYSIS
Participants were grouped into the following proteinuria categories based on their urinary test results: normoalbuminuria (persons with negative test results for both microalbuminuria and gross proteinuria), microalbuminuria (those testing negative for gross proteinuria but testing positive for microalbuminuria), and gross proteinuria.
After examining the frequency distribution of all variables, the associations between the proteinuria groups and possible confounding variables were assessed by  2 analysis and analysis of variance. Mortality rates were expressed as the number of deaths from cardiovascular disease per 1000 person-years accrued for each cohort member. This was based on the length of follow-up, calculated as the number of days from the date of the 1984-1986 examination to the date of death, date of last contact, or December 31, 1996, whichever was earliest. The relation of proteinuria and subsequent mortality from cardiovascular disease was examined with Kaplan-Meier analysis.50 To evaluate whether mortality differed by proteinuria groups, the log-rank test51 was used. Multivariate analysis was performed using Cox proportional hazards regression,52 with 2 indicator variables created for the groups with microalbuminuria and gross proteinuria, which compared them with the group with normoalbuminuria. Initial analyses involved adjustments for age and sex, and subsequent procedures further controlled for diabetes-related variables, other cardiovascular risk factors, and presence of comorbid conditions or their markers. The diabetes-related variables we examined included diabetes duration, insulin intake, oral glucose-lowering agent use, plasma C peptide levels (categorized as <0.03, 0.03-0.29, and  0.30 nmol/L), and glycemic control (grouped as "excellent," "good," and "take action" based on glycosylated hemoglobin values of <7.5, 7.5-8.6, and 8.7%, respectively, which corresponded to the current recommendations for glycemic control using hemoglobin A1c).45, 53 Cardiovascular risk factors included cigarette smoking (classified as never, former, current), physical activity (categorized as engaging in regular physical activity for >3, 1-3, or 0 times per week), education (<12, 12, >12 years of school completed), alcohol intake (classified as never drinkers, past-year nondrinkers, and drinkers with alcohol intake of <2 g/d, 2-13 g/d, and 14 g/d), body mass index (calculated as weight in kilograms divided by the square of the height in meters), systolic and diastolic blood pressures, history of hypertension (defined as systolic blood pressure of 160 mm Hg or a diastolic of 95 mm Hg or taking antihypertensive medications), and intake of medications such as aspirin and antihypertensive agents. The comorbid conditions (or their markers) we examined included the presence of peripheral neuropathy symptoms (defined as self-reported loss of tactile sensation in hands or feet or decreased ability to feel the hotness or coldness of things), the presence and severity of diabetic retinopathy (grouped into none, mild to early nonproliferative, moderate to severe nonproliferative, and proliferative retinopathy, based on fundus photographs graded in masked fashion using a modified Airlie House classification system),36, 54-55 and history of cardiovascular disease (defined as having prior angina, myocardial infarction or stroke, or intake of nitroglycerin or digoxin). Variables were successively entered in Cox regression models, which adjusted for age, sex, and glycemic control, starting from diabetes-related variables, to other cardiovascular risk factors, and finally, to comorbid conditions or complications, while retaining those that remained independently related to cardiovascular mortality. For a subset (n=400) of the total study sample for whom we had measurements on HDL-C, total cholesterol, and the ratio of total cholesterol to HDL-C, we repeated our multivariate analyses including each of these variables.
To check for possible effect modification, stratified analyses were performed on subgroups of participants defined by specific risk factors. Likelihood ratio tests were used to test for interactions in the proportional hazards models.
To further quantify the excess risk of cardiovascular disease mortality associated with the severity of clinical proteinuria, the risk in persons with gross proteinuria was further analyzed according to the presence or absence of possible renal insufficiency, defined as having a serum creatinine level of 176 µmol/L (2.0 mg/dL) or greater. Because gross proteinuria found in the 1984-1986 examination could be isolated, data on the presence of gross proteinuria in the 4 years before that examination (ie, in the 1980-1982 examination of the WESDR) were used to analyze separately the risk associated with (persistent) gross proteinuria found during both the 1980-1982 and 1984-1986 examinations. The presence of gross proteinuria was assessed in the same manner in both examinations.47, 56
We also checked whether any associations of microalbuminuria and gross proteinuria were evident only for short-term cardiovascular mortality by comparing the RRs across different lengths of follow-up (12-year vs 10-year, 8-year, and 6-year follow-up) or whether these relations would disappear when persons who died during the first 5 years were successively removed from the analysis, as suggested in previous studies.8, 19 Finally, the risks associated with microalbuminuria and gross proteinuria were also calculated for other end points, including coronary heart disease (CHD) mortality, stroke mortality, and all-cause mortality. Coronary heart disease mortality was defined as any mention of CHD (ICD-9 codes 410-414.9) and stroke mortality as any mention of stroke (ICD-9 codes 430-438.9) as a contributory cause of death on the death certificate.
The proportionality assumption for the Cox regression models was tested (using time-dependent covariates defined by the interaction between time and the proteinuria indicator variables) and met. Hazard ratios were reported as RRs with 95% confidence intervals (CIs). The analyses were done using SAS version 6.12 software (SAS Institute, Cary, NC).
RESULTS
Of the 987 participants in the 1984-1986 examination, 9 individuals had undergone dialysis and 138 individuals had missing information on microalbuminuria and/or gross proteinuria, leaving 840 participants in the final study sample. Compared with those in the final study sample, individuals who had missing data on urinary protein levels were older (mean age, 72.9 vs 67.9 years) and had lower blood pressures (mean systolic/diastolic pressures, 138.8/72.8 vs 143.3/75.7 mm Hg) and body mass indexes (mean, 27.2 vs 29.4 kg/m2). They also had a higher rate of cardiovascular disease history (49.6% vs 40.4%). They were essentially similar with respect to all the other variables we examined.
Of the 840 persons in the final study sample, 54.8% had no evidence of microalbuminuria or gross proteinuria, whereas 24.8% had only microalbuminuria and 20.5% had gross proteinuria.
Potential risk factors were not evenly distributed among the proteinuria groups (Table 1). Compared with persons with normoalbuminuria, those with increasing levels of proteinuria (from microalbuminuria to gross proteinuria) were older, more likely to be male and to be taking insulin, and less likely to be using oral glucose-lowering agents and alcohol. They also tended to have longer durations of diabetes, higher systolic blood pressures, lower levels of physical activity, and higher rates of retinopathy, neuropathy, prior cardiovascular diseases, and use of aspirin and antihypertensive agents. No clear patterns were observed for the other variables.
|
|
|
|
Table 1. Characteristics of Persons With Older-Onset Diabetes Mellitus Who Had Data on Microalbuminuria and Gross Proteinuria in the 1984-1986 Examination of the Wisconsin Epidemiologic Study of Diabetic Retinopathy*
|
|
|
During follow-up of up to 12 years (6127 person-years), we identified 364 deaths from cardiovascular disease. The overall cardiovascular disease mortality rate for the study cohort was 59.4 per 1000 person-years. The rate for those with normoalbuminuria was 36.9 per 1000 person-years, whereas the rates for those with microalbuminuria and gross proteinuria were 85.5 and 123.0 per 1000 person-years, respectively.
Compared with older-onset diabetic persons and normoalbuminuria, diabetic persons with microalbuminuria and gross proteinuria had significantly higher risks of death from cardiovascular disease (P<.001) (Figure 1). The age- and sex-adjusted RRs progressively increased across increasing levels of proteinuria (Table 2). Additional adjustments for significant diabetes-related variables and cardiovascular disease risk factors, which included glycemic control, insulin use, alcohol intake, physical activity, history of cardiovascular disease, intake of antihypertensive agents, and the presence and severity of diabetic retinopathy, showed that the associations for increasing proteinuria levels remained significant. The RRs (95% CIs) were 1.84 (1.42-2.40) and 2.61 (1.99-3.43) for those with microalbuminuria and gross proteinuria, respectively. Further control for other factors, which were not independently related to cardiovascular mortality in the presence of all variables in the earlier model, did not change the significant associations observed. In a subset of 400 persons with older-onset diabetes mellitus who had complete information on HDL-C and total cholesterol, similar multivariate models that included HDL-C, total cholesterol, or the ratio of total cholesterol to HDL-C still showed significantly higher risks for the groups with microalbuminuria and gross proteinuria (data not shown). In separate analyses of all these models, we also consistently found that the risk of cardiovascular mortality in those with gross proteinuria was significantly greater than in those with microalbuminuria.
|
|
|
|
Kaplan-Meier survival curves for cardiovascular disease mortality according to proteinuria levels, Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1984-1996.
|
|
|
|
|
|
|
Table 2. Mortality Rates and Relative Risks for Death From Cardiovascular Disease (CVD) According to Proteinuria Status in 840 Persons With Older-Onset Diabetes Mellitus, Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1984-1996
|
|
|
We also examined variables, including sex, hypertension history, smoking status, insulin intake, glycemic control, and cardiovascular disease history, for their potential to modify the direct relation between levels of proteinuria and fatal cardiovascular disease. Not one was significant as an interaction variable.
To determine the risk associated with the severity of nephropathy, we further analyzed those with gross proteinuria according to the presence or absence of possible renal insufficiency. Table 3 shows that diabetic patients with proteinuria who had serum creatinine levels of at least 176 µmol/L (2.0 mg/dL) had a substantially higher risk of cardiovascular disease mortality compared with those with normoalbuminuria. To separate those with possible isolated gross proteinuria, we additionally analyzed the risk of older-onset diabetic patients who tested positive for gross proteinuria in both the 1984-1986 and 1980-1982 examinations, also finding a greater risk for fatal cardiovascular disease in this subgroup (Table 4).
|
|
|
|
Table 3. Mortality Rates and Relative Risks for Death From Cardiovascular Disease (CVD) According to Levels of Severity of Proteinuria in 840 Persons With Older-Onset Diabetes Mellitus, Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1984-1996
|
|
|
|
|
|
|
Table 4. Mortality Rates and Relative Risks for Death From Cardiovascular Disease (CVD) According to Levels of Proteinuria in 840 Persons With Older-Onset Diabetes Mellitus, Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1984-1996
|
|
|
When persons who died during the first 5 years were removed from the proportional hazards regression analysis, the associations of microalbuminuria and gross proteinuria with cardiovascular mortality remained highly significant. The adjusted RRs (95% CIs), which controlled for all variables listed in the multivariate models in Table 2, were 2.30 (1.58-3.44) for microalbuminuria and 2.75 (1.75-4.31) for gross proteinuria. Similarly, the associations remained significant for shorter periods of follow-up. For example, the adjusted RRs (95% CIs) for microalbuminuria and gross proteinuria were 1.76 (1.32-2.33) and 2.57 (1.94-3.42), respectively, after 10 years of follow-up and 1.69 (1.18-2.43) and 2.73 (1.94-3.85), respectively, after 6 years of follow-up.
When the end point used was CHD mortality, stroke mortality, or total mortality, the risks associated with microalbuminuria and gross proteinuria remained significantly higher compared with the risk associated with normoalbuminuria (Table 5).
|
|
|
|
Table 5. Mortality Rates and Relative Risks for Death From Coronary Heart Disease, Stroke, and All Causes According to Proteinuria Status in 840 Persons With Older-Onset Diabetes Mellitus, Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1984-1996
|
|
|
COMMENT
In this population-based prospective study, we have shown that older-onset diabetic persons with microalbuminuria or gross proteinuria had higher risks of death from cardiovascular disease and all causes in general and from CHD and stroke in particular compared with diabetic persons with normoalbuminuria. Despite the initial relation between proteinuria levels and some cardiovascular risk factors at baseline, some of which were seen in previous studies, the increased risks were independent of several factors related to diabetes, cardiovascular disease, and survival.
Despite the numerous studies on the prognostic significance of urinary albumin excretion in diabetic and nondiabetic settings, there have been few epidemiologic data on the specific association between microalbuminuria and cardiovascular or coronary mortality in type 2 diabetes mellitus. Earlier studies2-8,10-14 on microalbuminuria in type 2 diabetes mellitus have focused mainly, if not solely, on total mortality. Subsequently, significant estimates of RRs for the association of microalbuminuria with deaths from cardiovascular disease16 and CHD9, 16 were reported. A 1997 meta-analysis reported a summary odds ratio for microalbuminuria and cardiovascular mortality or morbidity of 2.0 (95% CI, 1.4-2.7) as pooled from 6 European studies17; however, only 1 study15 included in the overview presented RR estimates that corrected for potentially confounding factors. Interestingly, a study57 in Japan found no difference in the cardiovascular death rates between diabetic patients with normoalbuminuria and those with microalbuminuria. Moreover, other studies in Europe15, 19, 29-30,58-59 and Australia16 found that the associations of microalbuminuria or urinary albumin excretion with coronary,16, 19 cardiovascular,15, 29, 58 macrovascular,30 or all-cause59 mortality were not independent of common cardiovascular and diabetes-related variables. Our multivariate analyses showed that persons with older-onset diabetes mellitus and microalbuminuria had a significant 1.8-fold increase in the risk for cardiovascular death and a 2-fold increase in the risk for CHD mortality compared with older-onset diabetic persons with normoalbuminuria.
Numerous studies2, 4-5,13, 20-21,23-26,28 involving patients with type 2 diabetes mellitus showed higher risks for overall mortality associated with clinical proteinuria or macroalbuminuria, but few presented RR estimates for cardiovascular12, 22, 27 or coronary60 mortality. Others found no or weak associations with macroalbuminuria.9-10,15 Our study unequivocally showed a graded increase in the risk for cardiovascular and CHD mortality associated with proteinuria. Moreover, when the group with gross proteinuria was characterized further by serum creatinine values to indicate possible renal insufficiency or by the presence of gross proteinuria 4 years before the current examination to indicate possible longer-term "exposure" to clinical proteinuria, the risks for both coronary (data not shown) and cardiovascular mortality were increased substantially. Our data also showed that both microalbuminuria and gross proteinuria significantly predicted long-term mortality due to cardiovascular disease.
A number of explanations have been proposed to account for the relation between urinary protein excretion and cardiovascular morbidity or mortality in type 2 diabetes mellitus. Albuminuria is associated with many cardiovascular disease risk factors, including hyperinsulinemia and insulin resistance.58, 61-62 Microalbuminuria can also be a risk marker of established cardiovascular disease. Interestingly, a recent study19 provided subgroup findings in men that showed that although microalbuminuria could precede the development of CHD in patients with type 2 diabetes mellitus, CHD could also precede the development of microalbuminuria, suggesting that both factors could result from common determinants. Perhaps the most plausible of all mechanisms linking albuminuria to cardiovascular disease is the concept that albuminuria is a marker of extensive endothelial dysfunction or generalized vasculopathy, which may lead to heightened atherogenetic states.63-65 Previous studies64-65 have described the association of microalbuminuria with impairment of fibrinolytic capacity and increased plasma levels of von Willebrand factor and transcapillary loss of albumin. Whether or not these are the actual mechanisms involved, it remains important to address the issue of preventing the unwanted burden associated with albuminuria in diabetes. Current evidence from clinical trials of patients with type 2 diabetes mellitus suggests that tight blood pressure control may reduce the risk of microalbuminuria in patients with hypertension66 and that angiotensin-converting enzyme inhibition with enalapril maleate can prevent or delay the progression of microalbuminuria to overt nephropathy in normotensive persons.67-68 Although it remains to be seen whether angiotensin-converting enzyme inhibitors and other antihypertensive agents can similarly influence the risk of cardiovascular events, older-onset diabetic persons with albuminuria may significantly profit from aggressive efforts to correct contributing risk factors such as hyperglycemia, hypertension, dyslipoproteinemia, smoking, obesity, and physical inactivity.
Bias seemed unlikely to greatly account for the observed associations in our study. Differential follow-up was not likely given the uniform vital status follow-up procedures used by staff masked to the participants' albuminuria status. The assignment of causes of death was also made without any knowledge of the participants' exposure status collected in the study. It is possible that selective mortality, as well as our methods to ascertain the presence of microalbuminuria and gross proteinuria, could have affected our prevalence rates for these conditions46, 69-70 and our estimates of RRs. However, the relations of various risk factors with microalbuminuria and gross proteinuria in our study were consistent with previous studies. Chance was possible, but it appeared unlikely to substantially affect our results, given the strength and consistency of the relations we found. A strength of the study was our ability to measure and control for cardiovascular and diabetes-related factors associated with survival, although other unmeasured conditions, such as congestive heart failure and other lipids, could still affect our estimates.
In summary, results from our study of persons with older-onset diabetes mellitus strongly suggest that both microalbuminuria and gross proteinuria are independently associated with subsequent mortality from all causes and from cardiovascular diseases (including stroke and CHD). Further data from population-based incidence studies and clinical trials, as well as from populations with a sizeable proportion of patients newly diagnosed as having diabetes, are needed to determine whether albuminuria is indeed an independent risk factor for the development of incident cardiovascular disease.
AUTHOR INFORMATION
Accepted for publication August 3, 1999.
This study was supported in part by research grant EY03083 from the National Institutes of Health, Bethesda, Md, and by the Mentor-Based Postdoctoral Fellowship Award from the American Diabetes Association (Dr R. Klein).
We thank the participants of the Wisconsin Epidemiologic Study of Diabetic Retinopathy for their dedication and commitment. We are also grateful for the assistance of the Wisconsin Center for Health Statistics. We thank Stacy Meuer, BA, and Lorraine Danforth, BA, for their help in data processing.
Corresponding author: Ronald Klein, MD, MPH, Department of Ophthalmology and Visual Sciences, University of Wisconsin–Madison Medical School, 610 N Walnut St, 460 WARF, Madison, WI 53705-2397 (e-mail: kleinr{at}epi.ophth.wisc.edu).
From the Department of Ophthalmology and Visual Sciences, University of Wisconsin–Madison Medical School.
REFERENCES
| |
1. Geiss LS, Herman WH, Smith PJ. Mortality in non–insulin-dependent diabetes. In: Anonymous Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995:233-257. NIH publication 95-1468.
2. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
ABSTRACT
3. Jarrett RJ, Viberti GC, Argyropoulos A, et al. Microalbuminuria predicts mortality in non–insulin-dependent diabetes. Diabet Med. 1984;1:17-19.
PUBMED
4. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non–insulin-dependent diabetes: a 10-year follow-up study of 503 patients. Diabet Med. 1988;5:126-134.
ISI
| PUBMED
5. Stiegler H, Standl E, Schulz K, Roth R, Lehmacher W. Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabet Med. 1992;9:646-653.
ISI
| PUBMED
6. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
ABSTRACT
7. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int. 1992;41:731-735.
ISI
| PUBMED
8. Damsgaard EM, Froland A, Jorgensen OD, Morgensen CE. Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia. 1993;36:1030-1036.
FULL TEXT
|
ISI
| PUBMED
9. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996-1003.
ABSTRACT
10. Neil HA, Hawkins MM, Potock MH, Mann JI. Prognostic value of urinary albumin concentration in diabetic patients surviving the first 5 years after assessment. Diabetologia. 1994;37:1287-1288.
FULL TEXT
|
ISI
| PUBMED
11. Lunt H, Graham PJ, Jury DR, et al. The prognostic significance of urinary albumin in Polynesians with non–insulin-dependent diabetes. Diabetes Res Clin Pract. 1994;25:141-145.
FULL TEXT
|
ISI
| PUBMED
12. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
ABSTRACT
13. Chan JC, Cheung CK, Cheung MY, et al. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care. 1995;18:1013-1016.
ABSTRACT
14. Beatty OL, Ritchie CM, Bell PM, Hadden DR, Kennedy L, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non–insulin-treated diabetes: an eight-year follow-up study. Diabet Med. 1995;12:261-266.
ISI
| PUBMED
15. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia. 1995;38:610-616.
ISI
| PUBMED
16. Beilin J, Stanton KG, McCann VJ, Knuiman MW, Divitini ML. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Aust N Z J Med. 1996;26:519-525.
ISI
| PUBMED
17. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non–insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
FREE FULL TEXT
18. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus: Risk Factor Intervention Study Group. Am J Cardiol. 1997;80:164-169.
FULL TEXT
|
ISI
| PUBMED
19. Mattock MB, Barnes DJ, Viberti G, et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes. 1998;47:1786-1792.
ABSTRACT
20. Pell S, D'Alonzo CA. Factors associated with long-term survival of diabetics. JAMA. 1970;214:1833-1840.
FREE FULL TEXT
21. Mihara T, Ohashi H, Hirata Y. Mortality and causes of death among Japanese diabetics in the Tokyo area: prospective follow-up study over four years. Tohoku J Exp Med. 1983;141(suppl):661-664.
22. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes. 1988;37:1499-1504.
ABSTRACT
23. Klein R, Moss SE, Klein BE, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med. 1989;149:266-272.
FREE FULL TEXT
24. Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients: a long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract. 1989;7:33-40.
FULL TEXT
|
ISI
| PUBMED
25. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics), II: associated risk factors. Diabetologia. 1990;33:542-548. [published erratum appears in Diabetologia. 1991;34:287].
ISI
26. Knuiman MW, Welborn TA, Whittall DE. An analysis of excess mortality rates for persons with non–insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. Am J Epidemiol. 1992;135:638-648.
FREE FULL TEXT
27. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med. 1995;12:149-155.
ISI
| PUBMED
28. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T. A 15-year follow-up study of patients with non–insulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan: factors predictive of the prognosis of diabetic patients. Diabetes Res Clin Pract. 1997;36:41-47.
FULL TEXT
|
ISI
| PUBMED
29. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non–insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1184.
FULL TEXT
|
ISI
| PUBMED
30. Standl E, Schnell O, Balletshofer B, et al. Influence of diabetes mellitus on the heart and macrovascular mortality. Diabetologia. 1997;40(suppl 2):S125-S126.
31. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol. 1984;119:54-61.
FREE FULL TEXT
32. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
FREE FULL TEXT
33. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, III: prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527-532.
FREE FULL TEXT
34. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107:237-243.
FREE FULL TEXT
35. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, X: four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107:244-249.
FREE FULL TEXT
36. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIV: ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217-1228.
FREE FULL TEXT
37. Klein R, Klein BE, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care. 1993;16:1325-1330.
ABSTRACT
38. Hypertension Detection and Follow-up Program Cooperative Group. The hypertension detection and follow-up program. Prev Med. 1976;5:207-215.
FULL TEXT
|
ISI
| PUBMED
39. Diabetic Retinopathy Study. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 1981;21:210-226.
ISI
| PUBMED
40. Moss SE, Klein R, Klein BE, Spennetta TL, Shrago ES. Methodologic considerations in measuring glycosylated hemoglobin in epidemiologic studies. J Clin Epidemiol. 1988;41:645-649.
FULL TEXT
|
ISI
| PUBMED
41. Faber OK, Binder C, Markussen J, et al. Characterization of seven C-peptide antisera. Diabetes. 1978;27(suppl 1):170-177.
42. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of specificity. J Biol Chem. 1958;195:357-366.
43. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977;23:882-884.
FREE FULL TEXT
44. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
ISI
| PUBMED
45. The Diabetes Control and Complications Trial Research Group, Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1995;155:745-754.
FREE FULL TEXT
46. Klein R, Klein BE, Linton KL, Moss SE. Microalbuminuria in a population-based study of diabetes. Arch Intern Med. 1992;152:153-158.
FREE FULL TEXT
47. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med. 1988;148:181-186.
FREE FULL TEXT
48. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
49. Crews DE, Stamler J, Dyer A. Conditions other than underlying cause of death listed on death certificates provide additional useful information for epidemiologic research. Epidemiology. 1991;2:271-275.
PUBMED
50. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
FULL TEXT
|
ISI
51. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc Ser A. 1972;135:185-206.
FULL TEXT
52. Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;34:187-220.
53. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1998;21(suppl 1):S23-S31.
54. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report 10. Ophthalmology. 1991;98:786-806.
ISI
| PUBMED
55. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report 12. Ophthalmology 1991;98:823-833.
ISI
| PUBMED
56. Klein R, Klein BE, Moss SE. Incidence of gross proteinuria in older-onset diabetes: a population-based perspective. Diabetes. 1993;42:381-389.
ABSTRACT
57. Araki S, Haneda M, Togawa M, et al. Microalbuminuria is not associated with cardiovascular death in Japanese NIDDM. Diabetes Res Clin Pract. 1997;35:35-40.
FULL TEXT
|
ISI
| PUBMED
58. Niskanen LK, Penttila I, Parviainen M, Uusitupa MI. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19:486-493.
ABSTRACT
59. Wirta O, Pasternack A, Mustonen J, Laippala P. Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non–insulin-dependent diabetic subjects. Nephrol Dial Transplant. 1997;12:2612-2617.
FREE FULL TEXT
60. Nelson RG, Sievers ML, Knowler WC, et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non–insulin-dependent diabetes. Circulation. 1990;81:987-995.
FREE FULL TEXT
61. Alzaid AA. Microalbuminuria in patients with NIDDM: an overview. Diabetes Care. 1996;19:79-89.
ABSTRACT
62. Nosadini R, Brocco E. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes. Exp Clin Endocrinol Diabetes. 1997;105(suppl 2):1-7.
63. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219-226.
FULL TEXT
|
ISI
| PUBMED
64. Jensen T. Micro-albuminuria and large vessel disease in diabetes. J Hypertens Suppl. 1992;10:S21-S24.
65. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
FREE FULL TEXT
66. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
FREE FULL TEXT
67. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576-1581.
ABSTRACT
68. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non–insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
FREE FULL TEXT
69. James GP, Bee DE, Fuller JB. Proteinuria: accuracy and precision of laboratory diagnosis by dip-stick analysis. Clin Chem. 1978;24:1934-1939.
FREE FULL TEXT
70. Klein R, Klein BE, Moss SE. The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus. Arch Intern Med. 1991;151:1344-1348.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(8):1206-1207.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
Delea et al.
J. Am. Soc. Nephrol. 2009;20:2205-2213.
ABSTRACT
| FULL TEXT
Counterpoint: Clinical Islet Transplantation: Not Ready for Prime Time
Khan and Harlan
Diabetes Care 2009;32:1570-1574.
FULL TEXT
Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
Ninomiya et al.
J. Am. Soc. Nephrol. 2009;20:1813-1821.
ABSTRACT
| FULL TEXT
Changes in Albumin Excretion in the Diabetes Prevention Program
Diabetes Prevention Program Research Group
Diabetes Care 2009;32:720-725.
ABSTRACT
| FULL TEXT
Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease
Radbill et al.
Mayo Clin Proc. 2008;83:1373-1381.
ABSTRACT
| FULL TEXT
Screening for Kidney Diseases: Older Measures versus Novel Biomarkers
Wu and Parikh
CJASN 2008;3:1895-1901.
ABSTRACT
| FULL TEXT
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease
Shepherd et al.
Mayo Clin Proc. 2008;83:870-879.
ABSTRACT
| FULL TEXT
Proliferative Diabetic Retinopathy in Type 2 Diabetes Is Related to Coronary Artery Calcium in the Veterans Affairs Diabetes Trial (VADT)
Reaven et al.
Diabetes Care 2008;31:952-957.
ABSTRACT
| FULL TEXT
Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker
Wang et al.
Eur J Endocrinol 2008;158:317-322.
ABSTRACT
| FULL TEXT
Reliability of Urinary Albumin, Total Protein, and Creatinine Assays after Prolonged Storage: The Family Investigation of Nephropathy and Diabetes
Parekh et al.
CJASN 2007;2:1156-1162.
ABSTRACT
| FULL TEXT
Association between Glycosylated Hemoglobin Level and Cardiovascular and All-Cause Mortality in Type 1 Diabetes
Shankar et al.
Am J Epidemiol 2007;166:393-402.
ABSTRACT
| FULL TEXT
Diabetes Management Issues for Patients With Chronic Kidney Disease
Cavanaugh
Clin. Diabetes 2007;25:90-97.
ABSTRACT
| FULL TEXT
The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT
| FULL TEXT
Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model
Campbell et al.
The Annals of Pharmacotherapy 2007;41:1101-1110.
ABSTRACT
| FULL TEXT
Deletion of Protein Kinase C-{beta} Isoform In Vivo Reduces Renal Hypertrophy but Not Albuminuria in the Streptozotocin-Induced Diabetic Mouse Model
Meier et al.
Diabetes 2007;56:346-354.
ABSTRACT
| FULL TEXT
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease
Sarafidis and Bakris
Nephrol Dial Transplant 2006;21:2366-2374.
FULL TEXT
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT
| FULL TEXT
Normotensive Women With Type 2 Diabetes and Microalbuminuria Are at High Risk for Macrovascular Disease
Zandbergen et al.
Diabetes Care 2006;29:1851-1855.
ABSTRACT
| FULL TEXT
Managing hypertension in patients with type 2 diabetes mellitus.
Dobesh
Am J Health Syst Pharm 2006;63:1140-1149.
ABSTRACT
| FULL TEXT
Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria
de Mello et al.
Am. J. Clin. Nutr. 2006;83:1032-1038.
ABSTRACT
| FULL TEXT
Higher Levels of HDL Cholesterol Are Associated With a Decreased Likelihood of Albuminuria in Patients With Long-Standing Type 1 Diabetes
Molitch et al.
Diabetes Care 2006;29:78-82.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
Rosen et al.
ANN INTERN MED 2005;143:89-99.
ABSTRACT
| FULL TEXT
Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study report no. 27
Cusick et al.
Diabetes Care 2005;28:617-625.
ABSTRACT
| FULL TEXT
Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population
Furtner et al.
Eur Heart J 2005;26:279-287.
ABSTRACT
| FULL TEXT
A Prognostic Role of Mean 24-h Pulse Pressure Level for Cardiovascular Events in Type 2 Diabetic Subjects Under 60 Years of Age
Nakano et al.
Diabetes Care 2005;28:95-100.
ABSTRACT
| FULL TEXT
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
Gross et al.
Diabetes Care 2005;28:164-176.
ABSTRACT
| FULL TEXT
Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy
Barnett et al.
NEJM 2004;351:1952-1961.
ABSTRACT
| FULL TEXT
Effect of Angiotensin-Converting Enzyme Inhibition on Survival in 3773 Chinese Type 2 Diabetic Patients
So et al.
Hypertension 2004;44:294-299.
ABSTRACT
| FULL TEXT
Diminished Loss of Proteoglycans and Lack of Albuminuria in Protein Kinase C-{alpha}--Deficient Diabetic Mice
Menne et al.
Diabetes 2004;53:2101-2109.
ABSTRACT
| FULL TEXT
Disappearance of Microalbuminuria in a Patient With Type 2 Diabetes and the Metabolic Syndrome in the Setting of an Intense Exercise and Dietary Program With Sustained Weight Reduction
Fredrickson et al.
Diabetes Care 2004;27:1754-1755.
FULL TEXT
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Sarnak et al.
Hypertension 2003;42:1050-1065.
FULL TEXT
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Sarnak et al.
Circulation 2003;108:2154-2169.
FULL TEXT
Prospective Evaluation of Carotid Bruit as a Predictor of First Stroke in Type 2 Diabetes: The Fremantle Diabetes Study
Gillett et al.
Stroke 2003;34:2145-2151.
ABSTRACT
| FULL TEXT
Renal function and cardiovascular risk markers in a remote Australian Aboriginal community
McDonald et al.
Nephrol Dial Transplant 2003;18:1555-1561.
ABSTRACT
| FULL TEXT
Renal function and cardiovascular risk markers in a remote Australian Aboriginal community
McDonald et al.
Nephrol Dial Transplant 2003;18:1555-1561.
ABSTRACT
| FULL TEXT
Low Incidence of End-Stage Renal Disease and Chronic Renal Failure in Type 2 Diabetes: A 10-year prospective study
Bruno et al.
Diabetes Care 2003;26:2353-2358.
ABSTRACT
| FULL TEXT
Progression to Overt Nephropathy in Type 2 Diabetes: The Casale Monferrato Study
Bruno et al.
Diabetes Care 2003;26:2150-2155.
ABSTRACT
| FULL TEXT
Disparities in Use of Lipid-Lowering Medications Among People With Type 2 Diabetes Mellitus
Safford et al.
Arch Intern Med 2003;163:922-928.
ABSTRACT
| FULL TEXT
Incidence of Retinopathy and Nephropathy in Youth-Onset Compared With Adult-Onset Type 2 Diabetes
Krakoff et al.
Diabetes Care 2003;26:76-81.
ABSTRACT
| FULL TEXT
The Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet, on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects With or Without Type 2 Diabetes
Tong et al.
Arch Intern Med 2002;162:2428-2435.
ABSTRACT
| FULL TEXT
Concomitance of Diabetic Retinopathy and Proteinuria Accelerates the Rate of Decline of Kidney Function in Type 2 Diabetic Patients
Trevisan et al.
Diabetes Care 2002;25:2026-2031.
ABSTRACT
| FULL TEXT
Animal Versus Plant Protein Meals in Individuals With Type 2 Diabetes and Microalbuminuria: Effects on renal, glycemic, and lipid parameters
Wheeler et al.
Diabetes Care 2002;25:1277-1282.
ABSTRACT
| FULL TEXT
Longitudinal Association of Glycemia and Microalbuminuria: The Framingham Offspring Study
Meigs et al.
Diabetes Care 2002;25:977-983.
ABSTRACT
| FULL TEXT
Renal Outcome in Type 2 Diabetic Patients With or Without Coexisting Nondiabetic Nephropathies
Wong et al.
Diabetes Care 2002;25:900-905.
ABSTRACT
| FULL TEXT
Smoking and proteinuria impair vasodilatory response of intrarenal arteries to nitroglycerine in patients with type 2 diabetes mellitus
Matsumoto et al.
Nephrol Dial Transplant 2002;17:608-613.
ABSTRACT
| FULL TEXT
Diabetic renal disease: who to refer, when to refer
Page
British Journal of Diabetes & Vascular Disease 2002;2:112-114.
Renal Insufficiency and Subsequent Death Resulting from Cardiovascular Disease in the United States
Muntner et al.
J. Am. Soc. Nephrol. 2002;13:745-753.
ABSTRACT
| FULL TEXT
The Kidney in Cardiovascular Disease
Kasiske
ANN INTERN MED 2001;134:707-709.
FULL TEXT
|
